Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pfs25-Pfs230 malaria vaccine - MVI

Drug Profile

Pfs25-Pfs230 malaria vaccine - MVI

Alternative Names: Pfs230D1-EPA/Matrix-M Vaccine; PFS25 VLP & Pfs230 VLP; Pfs25-Pfs230 virus-like particle malaria vaccine - MVI; Pfs25/Alhydrogel and Pfs230D1M-EPA/Alhydrogel; Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01

Latest Information Update: 07 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Burnet Institute; Malaria Vaccine Initiative
  • Developer National Institute of Allergy and Infectious Diseases
  • Class Antimalarials; Parasitic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 21 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with Novavax completes phase I trial (In adults, Prevention) in Mali (NCT05135273)
  • 22 Oct 2021 National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with Novavax initiates phase I trial (In adults, Prevention) in Mali (NCT05135273)
  • 29 Sep 2021 Pfs25-Pfs230 malaria vaccine is still in phase II trials for Malaria (In children, In adults, In the elderly, Prevention) in Mali (Parenteral) (NCT03917654)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top